NovaBridge rises as cancer drug shows promise in early trial

NovaBridge Biosciences

06/01/2026 12:59

** Shares of drug developer NovaBridge NBP.O rise 6.41% to $4.65 premarket

** Co says its experimental cancer drug, givastomig, showed promising results when used with standard chemotherapy and immunotherapy in patients with advanced gastric cancer

** Study of 54 patients showed 77% and 73% response rates at two doses, says co

** NBP says lower dose delayed cancer progression for nearly 17 months; higher dose data pending

** Co plans global trial comparing drug to standard treatments early this year - NBP

** As of last close, stock up ~10% over the past year

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))